Global Biosimilar Contract Manufacturing Market

Biosimilar Contract Manufacturing Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others), Production Technology (Mammalian, Non-Mammalian) Players and Region - Global Market Outlook to 2030

Biosimilar Contract Manufacturing Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Biosimilar Contract Manufacturing Market Overview:
Biosimilar contract manufacturing is the process by which a pharmaceutical company, known as the contract manufacturing organization, produces biosimilar drugs on behalf of another company, typically a biopharmaceutical company. Biosimilars are biological products that are highly similar to an already-approved reference biologic, known as the originator or reference product. Biosimilar contract manufacturing plays a crucial role in expanding access to affordable biological therapies by increasing the availability of high-quality biosimilar products on the market. It also facilitates collaboration and partnerships between biopharmaceutical companies and contract manufacturing organizations to drive innovation and efficiency in the biopharmaceutical industry. As per latest study released by AMA Research, the Global Biosimilar Contract Manufacturing market is expected to see growth rate of 20.3%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Billion)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Shift towards Value-Based Healthcare Models and Cost-Effective Treatment Options

Market Growth Drivers:
Increasing demand for cost-effective biologic drugs. and Increasing Prevalence of Chronic Diseases

Challenges:
Ensuring Product Consistency and Quality Is Crucial In Biosimilar Manufacturing

Restraints:
Lack of skilled professionals in development and manufacturing. and Intellectual property issues.

Opportunities:
Technological advancement in production of biosimilar.

Competitive Landscape:
Biosimilar Contract Manufacturing is a fragmented market due to the presence of various players. The players are focusing on strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.
Some of the key players profiled in the report are Novartis AG (Switzerland), Pfizer Inc. (United States), Reddy’s Laboratories (India), Amgen Inc. (United States), Samsung Biologics (United States), Lonza (Switzerland), Boehringer Ingelheim Biopharmaceuticals (Germany), Catalent (United States), Biocon (India), IQVIA Inc. (United States), AGC Biologics (United States) and Thermo Fischer Scientific (United States). Additionally, following companies can also be profiled that are part of our coverage like Celltrion, Inc. (United States), Almac Group (United Kingdom), WuXi Biologics (China), Avid Bioservices, Inc (United States) and Alcami Corporation (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Biosimilar Contract Manufacturing market by 2030. Considering Market by Production Technology, the sub-segment i.e. Mammalian will boost the Biosimilar Contract Manufacturing market.

Latest Market Insights:
In November 2023, SwiftPharma and Canadian biopharmaceutical firm PlantForm Corporation established a contract manufacturing partnership. SwiftPharma will be manufacturing antibodies and proteins for PlantForm's product pipeline under this agreement.

In October 2023, Tanvex Biopharma Inc., a developer and manufacturer of biopharmaceutical, launched Tanvex CDMO to provide comprehensive biologic contract development and manufacturing services, offering its experience and expertise to the biopharmaceutical industry.

The Food and Drug Administration (FDA) is providing guidance on cooperative manufacturing arrangements for biological products regulated under Section 351 of the Public Health Service Act. This guidance is a collaboration between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). It outlines our current approach to licensing strategies to meet the growing demand for flexible manufacturing arrangements.

What Can be Explored with the Biosimilar Contract Manufacturing Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Biosimilar Contract Manufacturing Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Biosimilar Contract Manufacturing
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Biosimilar Contract Manufacturing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Biosimilar Contract Manufacturing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Biosimilar Manufacturer, Biosimilar Provider, Research and Development, Investor, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Recombinant Non-Glycosylated Proteins
  • Recombinant Glycosylated Proteins
By Application
  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic & Autoimmune Disorders
  • Rheumatoid Arthritis
  • Others
By Production Technology
  • Mammalian
  • Non-Mammalian

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing demand for cost-effective biologic drugs.
      • 3.2.2. Increasing Prevalence of Chronic Diseases
    • 3.3. Market Challenges
      • 3.3.1. Ensuring Product Consistency and Quality Is Crucial In Biosimilar Manufacturing
    • 3.4. Market Trends
      • 3.4.1. Shift towards Value-Based Healthcare Models and Cost-Effective Treatment Options
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biosimilar Contract Manufacturing, by Type, Application, Production Technology and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Biosimilar Contract Manufacturing (Value)
      • 5.2.1. Global Biosimilar Contract Manufacturing by: Type (Value)
        • 5.2.1.1. Recombinant Non-Glycosylated Proteins
        • 5.2.1.2. Recombinant Glycosylated Proteins
      • 5.2.2. Global Biosimilar Contract Manufacturing by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Blood Disorders
        • 5.2.2.3. Growth Hormonal Deficiency
        • 5.2.2.4. Chronic & Autoimmune Disorders
        • 5.2.2.5. Rheumatoid Arthritis
        • 5.2.2.6. Others
      • 5.2.3. Global Biosimilar Contract Manufacturing by: Production Technology (Value)
        • 5.2.3.1. Mammalian
        • 5.2.3.2. Non-Mammalian
      • 5.2.4. Global Biosimilar Contract Manufacturing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Biosimilar Contract Manufacturing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Reddy’s Laboratories (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Samsung Biologics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lonza (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Boehringer Ingelheim Biopharmaceuticals (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Catalent (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biocon (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. IQVIA Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. AGC Biologics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Thermo Fischer Scientific (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Biosimilar Contract Manufacturing Sale, by Type, Application, Production Technology and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Biosimilar Contract Manufacturing (Value)
      • 7.2.1. Global Biosimilar Contract Manufacturing by: Type (Value)
        • 7.2.1.1. Recombinant Non-Glycosylated Proteins
        • 7.2.1.2. Recombinant Glycosylated Proteins
      • 7.2.2. Global Biosimilar Contract Manufacturing by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Blood Disorders
        • 7.2.2.3. Growth Hormonal Deficiency
        • 7.2.2.4. Chronic & Autoimmune Disorders
        • 7.2.2.5. Rheumatoid Arthritis
        • 7.2.2.6. Others
      • 7.2.3. Global Biosimilar Contract Manufacturing by: Production Technology (Value)
        • 7.2.3.1. Mammalian
        • 7.2.3.2. Non-Mammalian
      • 7.2.4. Global Biosimilar Contract Manufacturing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biosimilar Contract Manufacturing: by Type(USD Billion)
  • Table 2. Biosimilar Contract Manufacturing Recombinant Non-Glycosylated Proteins , by Region USD Billion (2018-2023)
  • Table 3. Biosimilar Contract Manufacturing Recombinant Glycosylated Proteins , by Region USD Billion (2018-2023)
  • Table 4. Biosimilar Contract Manufacturing: by Application(USD Billion)
  • Table 5. Biosimilar Contract Manufacturing Oncology , by Region USD Billion (2018-2023)
  • Table 6. Biosimilar Contract Manufacturing Blood Disorders , by Region USD Billion (2018-2023)
  • Table 7. Biosimilar Contract Manufacturing Growth Hormonal Deficiency , by Region USD Billion (2018-2023)
  • Table 8. Biosimilar Contract Manufacturing Chronic & Autoimmune Disorders , by Region USD Billion (2018-2023)
  • Table 9. Biosimilar Contract Manufacturing Rheumatoid Arthritis , by Region USD Billion (2018-2023)
  • Table 10. Biosimilar Contract Manufacturing Others , by Region USD Billion (2018-2023)
  • Table 11. Biosimilar Contract Manufacturing: by Production Technology(USD Billion)
  • Table 12. Biosimilar Contract Manufacturing Mammalian , by Region USD Billion (2018-2023)
  • Table 13. Biosimilar Contract Manufacturing Non-Mammalian , by Region USD Billion (2018-2023)
  • Table 14. South America Biosimilar Contract Manufacturing, by Country USD Billion (2018-2023)
  • Table 15. South America Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 16. South America Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 17. South America Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 18. Brazil Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 19. Brazil Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 20. Brazil Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 21. Argentina Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 22. Argentina Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 23. Argentina Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 24. Rest of South America Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 25. Rest of South America Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 26. Rest of South America Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 27. Asia Pacific Biosimilar Contract Manufacturing, by Country USD Billion (2018-2023)
  • Table 28. Asia Pacific Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 29. Asia Pacific Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 30. Asia Pacific Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 31. China Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 32. China Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 33. China Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 34. Japan Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 35. Japan Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 36. Japan Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 37. India Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 38. India Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 39. India Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 40. South Korea Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 41. South Korea Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 42. South Korea Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 43. Taiwan Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 44. Taiwan Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 45. Taiwan Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 46. Australia Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 47. Australia Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 48. Australia Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 49. Rest of Asia-Pacific Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 50. Rest of Asia-Pacific Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 51. Rest of Asia-Pacific Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 52. Europe Biosimilar Contract Manufacturing, by Country USD Billion (2018-2023)
  • Table 53. Europe Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 54. Europe Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 55. Europe Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 56. Germany Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 57. Germany Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 58. Germany Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 59. France Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 60. France Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 61. France Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 62. Italy Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 63. Italy Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 64. Italy Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 65. United Kingdom Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 66. United Kingdom Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 67. United Kingdom Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 68. Netherlands Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 69. Netherlands Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 70. Netherlands Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 71. Rest of Europe Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 72. Rest of Europe Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 73. Rest of Europe Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 74. MEA Biosimilar Contract Manufacturing, by Country USD Billion (2018-2023)
  • Table 75. MEA Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 76. MEA Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 77. MEA Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 78. Middle East Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 79. Middle East Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 80. Middle East Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 81. Africa Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 82. Africa Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 83. Africa Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 84. North America Biosimilar Contract Manufacturing, by Country USD Billion (2018-2023)
  • Table 85. North America Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 86. North America Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 87. North America Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 88. United States Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 89. United States Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 90. United States Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 91. Canada Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 92. Canada Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 93. Canada Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 94. Mexico Biosimilar Contract Manufacturing, by Type USD Billion (2018-2023)
  • Table 95. Mexico Biosimilar Contract Manufacturing, by Application USD Billion (2018-2023)
  • Table 96. Mexico Biosimilar Contract Manufacturing, by Production Technology USD Billion (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Biosimilar Contract Manufacturing: by Type(USD Billion)
  • Table 110. Biosimilar Contract Manufacturing Recombinant Non-Glycosylated Proteins , by Region USD Billion (2025-2030)
  • Table 111. Biosimilar Contract Manufacturing Recombinant Glycosylated Proteins , by Region USD Billion (2025-2030)
  • Table 112. Biosimilar Contract Manufacturing: by Application(USD Billion)
  • Table 113. Biosimilar Contract Manufacturing Oncology , by Region USD Billion (2025-2030)
  • Table 114. Biosimilar Contract Manufacturing Blood Disorders , by Region USD Billion (2025-2030)
  • Table 115. Biosimilar Contract Manufacturing Growth Hormonal Deficiency , by Region USD Billion (2025-2030)
  • Table 116. Biosimilar Contract Manufacturing Chronic & Autoimmune Disorders , by Region USD Billion (2025-2030)
  • Table 117. Biosimilar Contract Manufacturing Rheumatoid Arthritis , by Region USD Billion (2025-2030)
  • Table 118. Biosimilar Contract Manufacturing Others , by Region USD Billion (2025-2030)
  • Table 119. Biosimilar Contract Manufacturing: by Production Technology(USD Billion)
  • Table 120. Biosimilar Contract Manufacturing Mammalian , by Region USD Billion (2025-2030)
  • Table 121. Biosimilar Contract Manufacturing Non-Mammalian , by Region USD Billion (2025-2030)
  • Table 122. South America Biosimilar Contract Manufacturing, by Country USD Billion (2025-2030)
  • Table 123. South America Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 124. South America Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 125. South America Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 126. Brazil Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 127. Brazil Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 128. Brazil Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 129. Argentina Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 130. Argentina Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 131. Argentina Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 132. Rest of South America Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 133. Rest of South America Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 134. Rest of South America Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 135. Asia Pacific Biosimilar Contract Manufacturing, by Country USD Billion (2025-2030)
  • Table 136. Asia Pacific Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 137. Asia Pacific Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 138. Asia Pacific Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 139. China Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 140. China Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 141. China Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 142. Japan Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 143. Japan Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 144. Japan Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 145. India Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 146. India Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 147. India Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 148. South Korea Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 149. South Korea Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 150. South Korea Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 151. Taiwan Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 152. Taiwan Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 153. Taiwan Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 154. Australia Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 155. Australia Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 156. Australia Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 157. Rest of Asia-Pacific Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 158. Rest of Asia-Pacific Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 159. Rest of Asia-Pacific Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 160. Europe Biosimilar Contract Manufacturing, by Country USD Billion (2025-2030)
  • Table 161. Europe Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 162. Europe Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 163. Europe Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 164. Germany Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 165. Germany Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 166. Germany Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 167. France Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 168. France Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 169. France Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 170. Italy Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 171. Italy Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 172. Italy Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 173. United Kingdom Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 174. United Kingdom Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 175. United Kingdom Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 176. Netherlands Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 177. Netherlands Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 178. Netherlands Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 179. Rest of Europe Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 180. Rest of Europe Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 181. Rest of Europe Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 182. MEA Biosimilar Contract Manufacturing, by Country USD Billion (2025-2030)
  • Table 183. MEA Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 184. MEA Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 185. MEA Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 186. Middle East Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 187. Middle East Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 188. Middle East Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 189. Africa Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 190. Africa Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 191. Africa Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 192. North America Biosimilar Contract Manufacturing, by Country USD Billion (2025-2030)
  • Table 193. North America Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 194. North America Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 195. North America Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 196. United States Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 197. United States Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 198. United States Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 199. Canada Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 200. Canada Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 201. Canada Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 202. Mexico Biosimilar Contract Manufacturing, by Type USD Billion (2025-2030)
  • Table 203. Mexico Biosimilar Contract Manufacturing, by Application USD Billion (2025-2030)
  • Table 204. Mexico Biosimilar Contract Manufacturing, by Production Technology USD Billion (2025-2030)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biosimilar Contract Manufacturing: by Type USD Billion (2018-2023)
  • Figure 5. Global Biosimilar Contract Manufacturing: by Application USD Billion (2018-2023)
  • Figure 6. Global Biosimilar Contract Manufacturing: by Production Technology USD Billion (2018-2023)
  • Figure 7. South America Biosimilar Contract Manufacturing Share (%), by Country
  • Figure 8. Asia Pacific Biosimilar Contract Manufacturing Share (%), by Country
  • Figure 9. Europe Biosimilar Contract Manufacturing Share (%), by Country
  • Figure 10. MEA Biosimilar Contract Manufacturing Share (%), by Country
  • Figure 11. North America Biosimilar Contract Manufacturing Share (%), by Country
  • Figure 12. Global Biosimilar Contract Manufacturing share by Players 2023 (%)
  • Figure 13. Global Biosimilar Contract Manufacturing share by Players (Top 3) 2023(%)
  • Figure 14. Global Biosimilar Contract Manufacturing share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Reddy’s Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 21. Reddy’s Laboratories (India) Revenue: by Geography 2023
  • Figure 22. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Samsung Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 25. Samsung Biologics (United States) Revenue: by Geography 2023
  • Figure 26. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Lonza (Switzerland) Revenue: by Geography 2023
  • Figure 28. Boehringer Ingelheim Biopharmaceuticals (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Boehringer Ingelheim Biopharmaceuticals (Germany) Revenue: by Geography 2023
  • Figure 30. Catalent (United States) Revenue, Net Income and Gross profit
  • Figure 31. Catalent (United States) Revenue: by Geography 2023
  • Figure 32. Biocon (India) Revenue, Net Income and Gross profit
  • Figure 33. Biocon (India) Revenue: by Geography 2023
  • Figure 34. IQVIA Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. IQVIA Inc. (United States) Revenue: by Geography 2023
  • Figure 36. AGC Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 37. AGC Biologics (United States) Revenue: by Geography 2023
  • Figure 38. Thermo Fischer Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 39. Thermo Fischer Scientific (United States) Revenue: by Geography 2023
  • Figure 40. Global Biosimilar Contract Manufacturing: by Type USD Billion (2025-2030)
  • Figure 41. Global Biosimilar Contract Manufacturing: by Application USD Billion (2025-2030)
  • Figure 42. Global Biosimilar Contract Manufacturing: by Production Technology USD Billion (2025-2030)
  • Figure 43. South America Biosimilar Contract Manufacturing Share (%), by Country
  • Figure 44. Asia Pacific Biosimilar Contract Manufacturing Share (%), by Country
  • Figure 45. Europe Biosimilar Contract Manufacturing Share (%), by Country
  • Figure 46. MEA Biosimilar Contract Manufacturing Share (%), by Country
  • Figure 47. North America Biosimilar Contract Manufacturing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Reddy’s Laboratories (India)
  • Amgen Inc. (United States)
  • Samsung Biologics (United States)
  • Lonza (Switzerland)
  • Boehringer Ingelheim Biopharmaceuticals (Germany)
  • Catalent (United States)
  • Biocon (India)
  • IQVIA Inc. (United States)
  • AGC Biologics (United States)
  • Thermo Fischer Scientific (United States)
Additional players considered in the study are as follows:
Celltrion, Inc. (United States) , Almac Group (United Kingdom) , WuXi Biologics (China) , Avid Bioservices, Inc (United States) , Alcami Corporation (United States) ,
Select User Access Type

Key Highlights of Report


Mar 2024 239 Pages 97 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biosimilar Contract Manufacturing Market Quantitative research analysis
Global Biosimilar Contract Manufacturing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Biosimilar Contract Manufacturing market are Novartis AG (Switzerland), Pfizer Inc. (United States), Reddy’s Laboratories (India), Amgen Inc. (United States), Samsung Biologics (United States), Lonza (Switzerland), Boehringer Ingelheim Biopharmaceuticals (Germany), Catalent (United States), Biocon (India), IQVIA Inc. (United States), AGC Biologics (United States) and Thermo Fischer Scientific (United States), to name a few.
"Shift towards Value-Based Healthcare Models and Cost-Effective Treatment Options" is seen as one of major influencing trends for Biosimilar Contract Manufacturing Market during projected period 2023-2030.
Recombinant Non-Glycosylated Proteins segment in Global market to hold robust market share owing to "Increasing demand for cost-effective biologic drugs. ".

Know More About Global Biosimilar Contract Manufacturing Market Report?

Have a Query? Click Here

Other Related Reports

Generic Pharmaceuticals- Comprehensive Study by Type (Biosimilars, Authorized Generics, Branded Generics, Specialty Generics, Others), Application (CNS, Cardiovascular, Dermatology, Genitourinary/Hor...
$ 3800
Vitamin C (Ascorbic Acid)- Comprehensive Study by Type (Sodium Ascorbate, Calcium Ascorbate, Potassium Ascorbate, Magnesium Ascorbate, D-Isoascorbic Acid, Granulation, Others), Application (Food and ...
$ 3800
Europe, Brazil, Australia, China, US Bariatric Food Supplements Comprehensive Study by Type (Protein Powder, Multivitamins & Minerals, Probiotics, Iron/Copper Products, Calcium Products, Others), For...
$ 3800